ArticleDrugs & therapy perspectives : for rational drug selection and use2022
Plasma lipid profile: a predictive marker of disease severity among COVID-19 patients-an opportunity for low-income countries.
Article in Drugs & therapy perspectives : for rational drug selection and use, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- Naringenin-loaded nanoparticles ameliorate scopolamine-induced neurotoxicity.Scientific reports · 2026Article
- Nutritional Evaluation and Free Radical Scavenging Activity of Nano-formulated Selenium-Moringa Peregrine Seed Extract as a Promising Suppressor of TGF-β1/P38/NF-kβ Signaling Pathway in HgClCurrent pharmaceutical biotechnology · 2026Article
- Moringa Peregrina-derived Selenium Nanoparticles: Potent Inhibitor of Key Inflammatory Pathways in Aluminum-exposed Rats.Pharmaceutical nanotechnology · 2026Article
- Design and Synthesis of Novel Spiropyridine Derivatives as Promising Anti-inflammatory and Gene-targeting Agents Against COVID-19.Current pharmaceutical design · 2026Article
- Ferulic acid-loaded chitosan nanoparticles enhance radiotherapy efficacy via STAT3 suppression and caspase-8/p53 activation in Ehrlich ascites carcinoma.Scientific reports · 2025Article
- Association between lipid profile and clinical outcomes in COVID-19 patients.Scientific reports · 2024Article
- Structure Activity Relationship and Molecular Docking of Some Quinazolines Bearing Sulfamerazine Moiety as New 3CLpro, cPLA2, sPLA2 Inhibitors.Molecules (Basel, Switzerland) · 2023Article
- Association of triglyceride/high-density lipoprotein cholesterol ratio with severe complications of COVID-19.Heliyon · 2023Article
- Angiotensin Converting Enzyme 1 Polymorphisms and Lipid Profile in Mexican Patients With COVID-19.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the correlation between body mass index (BMI) and plasma lipid profile levels in mild and severe COVID-19 patients. Method: This was a prospective, observational, cohort study, conducted in a medical referral center specializing in management of COVID-19 cases. Patients were divided into two groups according to infection severity (mild and severe). Blood samples were obtained from all patients who tested positive to a PCR test for measuring biochemical and inflammatory markers such as lactate dehydrogenase, ferritin, C-reactive protein, and d-dimer, as well as lipid profile, including total cholesterol, triacylglycerols, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), which were analyzed and compared between the two groups. Pearson's correlation was used to assess the correlation between BMI and plasma lipid profile among mild and severe cases. Results: The levels of plasma triacylglycerols, d-dimer, lactate dehydrogenase, ferritin, and C-reactive protein with severe infection were significantly different between patients with mild and severe COVID-19 symptoms ( Conclusion: A routine lipid profile test might help as a marker of inflammation and risk stratification in patients with COVID-19. Especially in middle- or low-income countries, the test can rapidly help clinicians to delineate prognostic measures and hence management and treatment plans for this disease as the levels of the lipid profile were correlated with the patients' BMI and infection severity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.